Credit Lyonnais has issued a research report raising AKESO's (09926) target price from HK$112.6 to HK$177, while maintaining its outperform rating. The report noted that the company's first-half 2025 sales increased 33.7% year-over-year, largely in line with market expectations. The firm has raised its sales forecasts for AKESO for 2025 to 2027 by 1.2%, 5.1%, and 18.9% respectively, while also increasing net profit forecasts for fiscal years 2026 and 2027 by 10.9% and 35% respectively. The report highlighted that AK112's overall survival (OS) analysis results are statistically significant and clinically meaningful, with this unexpectedly positive outcome expected to provide favorable reference data for the overseas HARMONi trial.